• ̍̍ CSE: BRAX
  • ̍̍ OTC: BRAXF
  • ̍̍ FWB: 4960
March 1, 2022

Braxia Scientific Reports Q3 2022 Financial Results; Company Leads in Psychedelic Research, Access and Therapist Training with First Multi-Dose Psilocybin Trial in Canada

  Achieved milestone with the start of landmark psilocybin clinical trial in Q3 2021- more than a dozen patients receive initial dose to date in first-ever Health Canada-approved, multi-dose psilocybin clinical trial in Canada Braxia Scientific funded psilocybin trial establishes psilocybin treatment framework for patients with Treatment Resistant Depression (TRD), provides patients immediate access to psychedelic treatments, and training for new therapists providing psilocybin-assisted therapy Clinics administer ~5,500 ketamine treatments to date across growing patient base in Canada   TORONTO, March 1, 2022 /CNW/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today announced the filing of its fiscal third-quarter results for the three-month period ending December 31, 2021. Complete financial statements along with related management discussion and analysis can be found...

January 31, 2022

Braxia Scientific Provides Update on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical Trials for Ketamine and Psilocybin Drug Development

  TORONTO, ONTARIO January 31, 2022 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today provided an update on the Company’s leading research role within the psychedelics industry. As the Company continues to focus on developing innovative treatments for depression, including potential ketamine derivatives, Braxia Scientific’s team of researchers also continue to carry out multiple psychedelic-based clinical research trials, adding to the Company’s large and growing proprietary dataset critical to informing future drug development. To date, Braxia Scientific has compiled comprehensive health data from administering more than 5,200 ketamine treatments at its network of clinics. Additionally, Braxia Scientific’s researchers have published 43 ketamine-related manuscripts in peer-reviewed biomedical journals, and the Canadian Rapid Treatment Centre of Excellence (CRTCE), a wholly owned Braxia...

January 6, 2022

Braxia Scientific Announces CAD$3 Million Private Placement with Institutional Investors

  TORONTO, ONTARIO – Jan. 6, 2022 – Braxia Scientific Corp. (the “Company” or “Braxia”), (CSE: BRAX) (FWB: 4960), a medical research company with clinics providing innovative psychedelic treatments for persons with depression and related disorders, is pleased to announce that it has entered into a securities purchase agreement with institutional investors for a private placement of its common shares (“Common Shares”) and warrants to purchase Common Shares (“Warrants”) for gross proceeds of approximately CAD$3 million (the “Private Placement”). Pursuant to the Private Placement, the Company will issue 30,000,000 Common Shares (or Common Share equivalents) and Warrants to purchase up to an aggregate of 30,000,000 Common Shares at a purchase price of CAD$0.10 per Common Share and associated Warrant. Each Warrant will entitle the holder to purchase one Common Share at an exercise price of CAD$0.125 per Common Share for a...

December 14, 2021

Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants Receive First Doses of Psilocybin

  Patients receive first dose in first-ever Health Canada-approved, multi-dose psilocybin clinical trial conducted at Braxia Scientific’s subsidiary CRTCE clinic Trial establishes psilocybin treatment framework for patients with TRD and opens new pathway for patients to access psychedelic treatment   TORONTO, ONTARIO December 14th, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative psychedelic treatments for persons with depression and related disorders, has reached a milestone as the first Health Canada-approved multiple-dose psilocybin clinical trial which commenced with first patients dosed in November 2021. The trial, which is being sponsored by the Brain and Cognition Discovery Foundation, is being conducted at the Canadian Rapid Treatment Center of Excellence (CRTCE), a wholly owned Braxia subsidiary, and includes adults with treatment-resistant depression (TRD) as part of bipolar or...

December 13, 2021

A PATIENT'S Q&A

A PATIENT'S JOURNEY

December 13, 2021
November 29, 2021

Second Quarter 2022 Financial Results; Corporate Update

Braxia Scientific Reports Second Quarter 2022 Financial Results and Provides Corporate Update   Expanded clinical infrastructure to support a growing portfolio of clinical trials of novel interventions and for drug discovery; 14 registered clinical trials in depression, led by Company CEO and Chief Medical and Scientific Officer, completed or in process Excellent progress on only psilocybin trial in Canada actively recruiting study participants to receive psilocybin-assisted therapy Clinical footprint in Canada has administered ~4,900 ketamine treatments to date; focus on expansion opportunities in the U.S. and Europe TORONTO, ONTARIO Nov. 29, 2021 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today announced the filing of its fiscal second-quarter results for the three-month period ending September 30,...

November 8, 2021

Advisory Board of KetaMD

Braxia Scientific CEO Dr. Roger McIntyre to Join Advisory Board of At-Home Telemedicine Platform KetaMD TORONTO, ONTARIO Nov. 9, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is delighted to announce that its CEO, Dr. Roger McIntyre, is joining KetaMD as an adviser. KetaMD, currently in beta, is a telemedicine platform in development that aims to provide affordable, potentially life-changing at-home medical ketamine treatments guided by registered nurses over telemedicine. Dr. McIntyre is a world-renowned expert in the treatment of depression and has contributed extensively to clinical practice guidelines for ketamine. He has been involved in nearly 750 published research endeavours centered around the treatment of mental health disorders. Dr. McIntrye is also the lead author...

November 8, 2021

Keynote at Wonderland: Miami

Braxia Scientific CEO Dr. Roger McIntyre to Deliver Keynote Address at Wonderland: Miami TORONTO, Ontario Nov. 8, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is delighted to announce that its CEO, Dr. Roger McIntyre, has been selected to be a keynote speaker at the Wonderland: Miami conference. The two-day event, which is scheduled to begin Mon., Nov. 8 at the Adrienne Arsht Center for the Performing Arts of Miami-Dade County, will act as a launching pad for innovative companies connected to the psychedelic medicine space. Dr. McIntyre will discuss the challenges patients with medication-resistant mental health issues face in accessing ketamine and other psychedelic therapies as well as developing new therapies. He will also outline...

November 2, 2021

Graduates First Cohort of Medical Professionals

Braxia Scientific Graduates First Cohort of Medical Professionals From Psilocybin-Assisted Therapy Training Program; Ready to Start Health Canada Approved Psilocybin Clinical Trial TORONTO, ONTARIO November 2, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is excited to announce the completion of the training program for psilocybin-assisted clinical therapy by its first multi-disciplinary cohort of 20 qualified therapists from diverse psychiatry and psychotherapy backgrounds. This program was implemented by the Braxia Institute, the Company’s training centre focused on advancing psychiatric clinical practice and health services of ketamine and psychedelic treatment therapy. Through this program, the Company is able to develop, train, and support qualified, independent medical physicians, psychologists and psychotherapists skilled in best practices to implement safe and...

October 29, 2021

Audio Webcast and Dial-In Number

Braxia Scientific Provides New Audio Webcast and Dial-In Number for Annual General Meeting TORONTO, ONTARIO, October 27, 2021 /CNW/ – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today provides revised details in connection with its annual general meeting of shareholders to be held on October 28, 2021, at 10:00 am (EST). The Company advises that the audio webcast and dial-in number for shareholders wishing to listen to the meeting have been changed from those provided in the notice of annual general meeting and information circular of the Company. The updated audio webcast and dial-in number is below: Audio Webcast Link: Click here for secure access Phone Number: +1-844-974-2903 Meeting Number: 2345 – 825 – 5938 Password: meet2021 Access Code: 234 – 582...